Dr. Razmik Mirzayans is currently appointed as Clinical Professor in the Division of Experimental Oncology in the Faculty of Medicine and Dentistry.
and human cell response to DNA damage
The overall aim of my research has been to characterize the homeostatic processes which enable cultured human cells to sense and respond to DNA-damaging agents. These homeostatic processes include DNA repair pathways and cell cycle checkpoints which facilitate repair of DNA damage, thereby preventing the accumulation of genomic instability, as well as the various late responses (i.e., delayed apoptosis, premature senescence) which eliminate cells with increased genomic instability from the proliferating population. Specifically, my research has contributed to the understanding of the roles of ATM, p53, p21(WAF1), and p16(INK4a) tumor
suppressors in these responses triggered by DNA-damaging agents. My current research is focused on lowering the apoptotic threshold by the use of non-cytotoxic pharmacological agents in an attempt to improve the outcome of breast cancer therapy by radiation and chemotherapeutic agents.